|
ハナフサ ノリオ
HANAFUSA, Norio
花房 規男 所属 医学部 医学科（東京女子医科大学病院） 職種 准教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy. |
| 掲載誌名 | 正式名：Renal replacement therapy 略 称：Ren Replace Ther ISSNコード：20591381/20591381 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 8(1),pp.18 |
| 著者・共著者 | Yoshifuji Ayumi, Ryuzaki Munekazu, Uehara Yuki, Ohmagari Norio, Kawai Toru, Kanno Yoshihiko, Kikuchi Kan, Kon Hiroshi, Sakai Ken, Shinoda Toshio, Takano Yaoko, Tanaka Junko, Hora Kazuhiko, Nakazawa Yasushi, Hasegawa Naoki, Hanafusa Norio, Hinoshita Fumihiko, Morikane Keita, Wakino Shu, Nakamoto Hidetomo, Takemoto Yoshiaki |
| 発行年月 | 2022 |
| 概要 | Background:Patients with coronavirus disease 2019 (COVID-19) who receive dialysis therapy develop more severe disease and have a poorer prognosis than patients who do not. Although various data on the treatment of patients not receiving dialysis therapy have been reported, clinical practice for patients on dialysis is challenging as data is limited. The Infection Control Committee of the Japanese Society for Dialysis Therapy decided to clarify the status of treatment in COVID-19 patients on dialysis.Methods:A questionnaire survey of 105 centers that had treated at least five COVID-19 patients on dialysis was conducted in August 2021.Results:Sixty-six centers (62.9%) responded to the questionnaire. Antivirals were administered in 27.7% of facilities treating mild disease (most patients received favipiravir) and 66.7% of facilities treating moderate disease (most patients with moderate or more severe conditions received remdesivir). Whether and how remdesivir is administered varies between centers. Steroids were initiated most frequently in moderate II disease (50.8%), while 43.1% of the facilities initiated steroids in mild or moderate I disease. The type of steroid, dose, and the duration of administration were generally consistent, with most facilities administering dexamethasone 6 mg orally or 6.6 mg intravenously for 10 days. Steroid pulse therapy was administered in 48.5% of the facilities, and tocilizumab was administered in 25.8% of the facilities, mainly to patients on ventilators or equivalent medications, or to the cases of exacerbations. Furthermore, some facilities used a polymethylmethacrylate membrane during dialysis, nafamostat as an anticoagulant, and continuous hemodiafiltration in severe cases. There was limited experience of polymyxin B-immobilized fiber column-direct hemoperfusion and extracorporeal membrane oxygenation. The discharge criteria for patients receiving dialysis therapy were longer than those set by the Ministry of Health, Labor and W |
| DOI | 10.1186/s41100-022-00405-8 |
| PMID | 35494536 |